TESARO

TESARO, Inc. was founded in 2010 as a private biopharmaceutical company focused on oncology, dedicated to improving the lives of cancer patients. The company plans to leverage the experience and capabilities of its management team to identify, acquire, and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent and selective neurokinin-1 receptor antagonist, which has completed Phase 2 clinical trials for the prevention of chemotherapy-induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. The Phase 3 clinical trial for rolapitant is planned to begin in 2011, with the first ALK inhibitor clinical trial scheduled to start in 2012.